EML4-ALK fusion gene in non-small cell lung cancer - PMC
When the EML4-ALK fusion gene is formed, it can be directly activated without the need for ligands, and abnormally activate downstream signaling pathways, promote cell proliferation and invasion, and inhibit apoptosis, ultimately leading to the occurrence of NSCLC.
EML4-ALK Mutations in Lung Cancer That Confer ...
Oct 28, 2010 · The EML4 (echinoderm microtubule-associated protein-like 4)–ALK (anaplastic lymphoma kinase) fusion-type tyrosine kinase is an oncoprotein found in 4 to 5% of non–small-cell...
ALK fusions in the pan-cancer setting: another tumor ...
Sep 29, 2023 · EML4 is the most common fusion partner in NSCLC, found most NSCLCs with ALK fusions 2. Still, some studies have identified more than a dozen ALK gene rearrangements involving various...
Molecular Anatomy of the EML4-ALK Fusion Protein for the …
Mar 18, 2023 · The EML4 (echinoderm microtubule-associated protein-like 4)-ALK (anaplastic lymphoma kinase) fusion gene in non-small-cell lung cancer (NSCLC) was first identified in 2007. As the EML4-ALK fusion protein promotes carcinogenesis in lung cells, much attention has been paid to it, leading to the development of therapies for patients with NSCLC.
Oncogenic EML4-ALK assemblies suppress growth factor ... - Nature
Nov 2, 2024 · Drug resistance remains a challenge for targeted therapy of cancers driven by EML4-ALK and related fusion oncogenes. EML4-ALK forms cytoplasmic protein condensates, which result from networks of ...
Genomic heterogeneity of ALK fusion breakpoints in non-
Jan 12, 2018 · In lung adenocarcinoma, canonical EML4-ALK inversion results in a fusion protein with a constitutively active ALK kinase domain. Evidence of ALK rearrangement occurs in a minority (2–7%) of lung...
The Biology and Treatment of EML4-ALK Non-Small Cell Lung Cancer
The fusion between echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) has recently been identified in a subset of non-small cell lung cancers (NSCLCs). EML4-ALK is most often detected in never smokers with lung cancer and has unique pathologic features.
Molecular mechanisms that underpin EML4-ALK driven ...
Jan 11, 2016 · ALK signalling is activated in cancer cells through three principal mechanisms: gene fusion events, such as NPM-ALK and EML4-ALK; ALK gene amplification; and activating point mutations such as F1174L in neuroblastoma (Fig. 2 b).
EML4-ALK Variants: Biological and Molecular Properties, and the …
Sep 5, 2017 · The EML4-ALK fusion protein is expressed in 2–9% of lung adenocarcinomas, and has also been identified in breast and colorectal cancers [7, 20, 21, 22]. The translocation occurs through a paracentric inversion between EML4 and ALK genes located in the short arm of chromosome 2.
Distribution of EML4-ALK fusion variants and clinical outcomes in ...
Jul 11, 2020 · EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK + non-small cell lung cancer
- Some results have been removed